Galmed Pharmaceuticals Ltd Files For Mixed Shelf Of Up To $200 Million - Sec Filing

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Here is a look at the most-searched stocks on Benzinga Pro for October 2024. Current prices and year-to-date performance are based on Nov. 1 and do not include dividends.

1. Tesla Inc

• Current Price: $248.98
• 52-Week Range: $138.80 to $273.54
• Year-to-Date Return: +0.2%
• July/August/September Ranking: 1st/3rd/3rd

2. NVIDIA Corporation

• Current Price: $135.37
• 52-Week Range: $44.90 to $144.42
• Year-to-Date Return: +181.0%
• July/August/September Ranking: 2nd/1st/1st

3. Trump Media & Technology Group

• Current Price: $30.56
• 52-Week Range: $11.75 to $79.38
• Year-to-Date Return: +75.7%
• July/August/September Ranking: Not in Top 20/Not in Top 20/20th

4. SPDR S&P 500 ETF Trust

• Current Price: $571.04
• 52-Week Range: $426.56 to $586.12
• Year-to-Date Return: +20.8%
• July/August/September Ranking: 3rd/2nd/2nd

5. Super Micro Computer Inc

• Current Price: $26.05
• 52-Week Range: $24.92 to $122.90
• Year-to-Date Return: -8.8%
• July/August/September Ranking: 19th/4th/7th

6. Bright Minds Biosciences Inc

• Current Price: $48.18
• 52-Week Range: $0.93 to $79.02
• Year-to-Date Return: +2,518.5%
• July/August/September Ranking: Not in Top 20 in Any

7. Advanced Micro Devices

• Current Price: $141.86
• 52-Week Range: $110.22 to $227.30
• Year-to-Date Return: +2.4%
• July/August/September Ranking: 14th/8th/Not in Top 20

8. Apple Inc

• Current Price: $222.91
• 52-Week Range: $164.08 to $237.49
• Year-to-Date Return: +20.1%
• July/August/September Ranking: 7th/6th/4th

9. Tevogen Bio Holdings

• Current Price: $2.37
• 52-Week Range: $0.26 to $21.09
• Year-to-Date Return: -78.7%
• July/August/September Ranking: Not in Top 20 in Any

10. Oklo Inc

• Current Price: $21.67
• 52-Week Range: $5.35 to $28.12
• Year-to-Date Return: +104.4%
• July/August/September Ranking: Not in Top 20 in Any

Did You Know?

• Congress Is Making Huge Investments. Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool

Honorable Mentions: The following stocks were the 11th to 20th most-searched tickers on Benzinga Pro in October 2024.

11. Amazon.com Inc

12. Microsoft Corporation

13. Meta Platforms

14. Palantir Technologies

15. Invesco QQQ Trust

16. MicroStrategy Inc

17. Genprex Inc

18. SoFi Technologies

19. Boeing Inc

20. TeraWulf Inc

Why It's Important: Tesla, regularly among the most searched tickers on the site, climbed the leaderboard to be the most-searched ticker on Benzinga Pro in October. The stock was third in the past two months, but ranked first in July.

Nvidia ranked second in October, dropping from first place over the last two months. The technology giant briefly passed Apple and Microsoft to be the most valuable company in the world.

One of the biggest movers in October was Trump Media & Technology Group, a media company co-founded by former President Donald Trump. The stock has surged in recent weeks ahead of Election Day. Trump's odds of winning the 2024 presidential election have increased across prediction markets and sports betting apps.

The stock has also been highlighted as a potential short-squeeze stock with high short interest. A 2024 election win by Trump could see the stock shoot higher. Likewise, the stock could fall significantly if Trump loses the election.

Trump Media & Technology Group will likely be among the most searched tickers on Benzinga Pro in November with Election Day happening on Nov. 5. The stock was the 20th most searched ticker in September and wasn't in the top 20 in August or July, ranking just outside the top 20.

The SPDR S&P 500 ETF Trust falls to fourth place from second in the past two months, likely due more to the surge in interest in the stocks mentioned above and not less interest in the S&P 500 market index. Although it should be noted that the Invesco QQQ Trust ETF, which tracks the Nasdaq 100 Index, fell from sixth place to 15th in October, potentially signaling less interest in ETFs and market indexes.

Other newcomers to the top 10 were Bright Minds Biosciences, Tevogen Bio and Oklo, who have each not previously been among the top 20 most-searched tickers in any given month. Tevogen shares have fallen significantly in 2024, while Bight Minds Sciences and Oklo are each up over 100% in 2024.

Advanced Micro Devices also returned to the top 10, ranking seventh, which comes after falling out of the top 20 in September. The stock has regularly gone back and forth between the top 10 and top 20 each month in 2024.

Dropping out of the top 10 along with Invesco QQQ were Wheeler Real Estate Investment Trust , Galmed Pharmaceuticals , Intel Corporation and Intuitive Machines .

Overall the month of October saw five of the same top 10 tickers from September and eight of the top 20 tickers from September.

Read Next:

• These 10 Stocks Were S&P 500’s Top Performers In Biden’s First Year: Could Trend Continue If Harris Wins 2024 Election?

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.

Here’s a look at the Benzinga Stock Whisper Index for the week of Sept. 20:

Barrick Gold : The gold-mining company saw increased interest from readers this week on the heels of a 50 basis point cut to interest rates by the Federal Reserve, which saw gold prices rise. The interest also comes after Barrick Gold CEO Mark Bristow spoke at the Gold Forum Americas earlier this week and said the company expects 30% growth in gold-equivalent ounces by the end of the decade from its existing assets.

Bristow's comments emphasized the company's current mines and those in development, as the industry experiences a surge in merger and acquisition activity. The CEO also highlighted how the company is expanding its copper portfolio, which could be something exciting to watch for investors.

Barrick shares were down 2% over the last five trading days, as seen on the Benzinga Pro chart below. The stock is up 14% year-to-date in 2024.

Galmed Pharmaceuticals Ltd shares are surging Thursday after the company announced plans to broaden its drug development activities over the next two years.

What Happened: Galmed announced that it plans to expand its drug development activities by adding two additional programs.

One program aims to identify novel Aramchol-based drug combinations to overcome resistance to standard-of-care oncological treatments for patients with advanced colorectal and hepatic cancers. The other program is expected to help discover new methods to allow the development of a novel Aramchol-based drug combination targeting cardiac fibrosis.

The clinical-stage biopharmaceutical company said it plans to release new data from in-vitro and ex-vivo studies on the aforementioned programs during the fourth quarter.

“The conditions Galmed plans to focus upon in the coming years are major public health problems impacting millions of people worldwide and posing huge financial burden on health providers,” said Allen Baharaff, president and CEO of Galmed Pharmaceuticals.

“SCD1 is a key enzyme that critically regulates many physiological processes, thereby promoting the progression of cardiovascular, cancer and neurodegenerative diseases. We are leveraging on two decades of development of the most clinically advanced SCD1 inhibitor (Aramchol) to date as we broaden our drug development activities.”

Check This Out: $1.8M Bet On Singular Genomics? Check Out These 3 Stocks Executives Are Buying

Galmed Pharmaceuticals is a very low-float stock with approximately 625,000 shares available for public trading, per Benzinga Pro. The company also had a market cap of less than $4.5 million as of Wednesday's close. Low-float, micro-cap stocks can be extremely volatile, which may help explain some of Thursday's surge.

Galmed’s average session volume over a 100-day period is approximately 1.711 million. Thursday’s trading volume has already crossed 16 million at the time of writing, according to Benzinga Pro.

GLMD Price Action: Galmed shares were up 53.6% at $10.60 at the time of publication, according to Benzinga Pro.

Photo: 3844328 from Pixabay.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.